

Ikuo Hirano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1287588/publications.pdf>

Version: 2024-02-01

185
papers

15,932
citations

34016

52
h-index

16605

123
g-index

192
all docs

192
docs citations

192
times ranked

5584
citing authors

#	ARTICLE	IF	CITATIONS
1	Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results From a Phase 3 Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 525-534.e10.	2.4	57
2	Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms After Dilation in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 766-775.e4.	2.4	21
3	Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1488-1498.e11.	2.4	21
4	Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 535-545.e15.	2.4	28
5	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 659-670.	1.5	40
6	Loss of Endothelial TSPAN12 Promotes Fibrostenotic Eosinophilic Esophagitis via Endothelial Cell-Fibroblast Crosstalk. <i>Gastroenterology</i> , 2022, 162, 439-453.	0.6	22
7	Esophageal Dysmotility Is Associated With Disease Severity in Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1719-1728.e3.	2.4	23
8	Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2022, 117, 264-271.	0.2	13
9	Evaluating Eosinophilic Colitis as a Unique Disease Using Colonic Molecular Profiles: A Multi-Site Study. <i>Gastroenterology</i> , 2022, 162, 1635-1649.	0.6	21
10	Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: A cross-sectional multi-center study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2520-2533.	2.7	15
11	Prospective Endoscopic Activity Assessment for Eosinophilic Gastritis in a Multisite Cohort. <i>American Journal of Gastroenterology</i> , 2022, 117, 413-423.	0.2	17
12	Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 1126-1137.e2.	0.5	18
13	Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2485-2494.e15.	2.4	16
14	International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2474-2484.e3.	2.4	57
15	Mast cell-pain connection in eosinophilic esophagitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1895-1899.	2.7	14
16	Impressions and aspirations from the FDA GREAT VI Workshop on Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis and Perspectives for Progress in the Field. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 844-853.	1.5	10
17	Development and Validation of Web-Based Tool to Predict Lamina Propria Fibrosis in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2022, 117, 272-279.	0.2	10
18	A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 33-47.	1.5	5

#	ARTICLE	IF	CITATIONS
19	A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. <i>Gastroenterology</i> , 2022, 163, 59-76.	0.6	33
20	Effectiveness and Safety of High- vs Low-Dose Swallowed Topical Steroids for Maintenance Treatment of Eosinophilic Esophagitis: A Multicenter Observational Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2514-2523.e2.	2.4	19
21	Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 699-706.e4.	2.4	19
22	Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 473-483.e17.	2.4	54
23	Food-induced immediate response of the esophagus? A newly identified syndrome in patients with eosinophilic esophagitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 339-347.	2.7	22
24	Eosinophilic Esophagitis: Etiology and Therapy. <i>Annual Review of Medicine</i> , 2021, 72, 183-197.	5.0	10
25	Low Prevalence of Extraesophageal Gastrointestinal Pathology in Patients with Eosinophilic Esophagitis. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	5
26	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	0
27	Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus. <i>Gastroenterology</i> , 2021, 161, 748-755.	0.6	11
28	A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. <i>Gastroenterology</i> , 2021, 161, 778-784.	0.6	0
29	619 HIGH DISCOVERY RATE OF GASTRODUODENAL EOSINOPHILIA BUT NOT EOSINOPHILIC ESOPHAGITIS IN PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.2	0
30	Esophageal Hypervigilance and Symptom-Specific Anxiety in Patients with Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2021, 161, 1133-1144.	0.6	42
31	Type 2 Immunity and Age Modify Gene Expression of Coronavirus-induced Disease 2019 Receptors in Eosinophilic Gastrointestinal Disorders. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 72, 718-722.	0.9	12
32	Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2020, 158, 111-122.e10.	0.6	300
33	Clinical relevance of esophageal subepithelial activity in eosinophilic esophagitis. <i>Journal of Gastroenterology</i> , 2020, 55, 249-260.	2.3	22
34	Emerging therapies for eosinophilic esophagitis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 38-45.	1.5	51
35	Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: Multi-site study. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 255-269.	1.5	51
36	Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2020, 158, 840-851.	0.6	67

#	ARTICLE	IF	CITATIONS
37	Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 28-37.	1.5	17
38	Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2024-2035.	1.1	44
39	Anti- α -Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. <i>New England Journal of Medicine</i> , 2020, 383, 1624-1634.	13.9	173
40	High Patient Disease Burden in a Cross-sectional, Multicenter Contact Registry Study of Eosinophilic Gastrointestinal Diseases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 71, 524-529.	0.9	19
41	MO1183 PREDICTORS OF RESPONSE TO CORTICOSTEROID THERAPY IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION. <i>Gastroenterology</i> , 2020, 158, S-817-S-818.	0.6	2
42	Maintenance Topical Steroid Therapy in Eosinophilic Esophagitis: Not So Hard to Swallow Any More?. <i>Gastroenterology</i> , 2020, 159, 1653-1655.	0.6	0
43	AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 416-423.	0.5	41
44	An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial results. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 367-376.e3.	1.5	32
45	Editorial: fluticasone propionate orally disintegrating tablets—interesting concept but is it going anywhere? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 990-991.	1.9	0
46	Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 750-759.	1.9	29
47	Clinical outcomes of adults with eosinophilic esophagitis with severe stricture. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 44-53.	0.5	14
48	AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2020, 158, 1776-1786.	0.6	188
49	Spotlight: Treatment of Eosinophilic Esophagitis (EoE). <i>Gastroenterology</i> , 2020, 158, 1788.	0.6	8
50	Wirksamkeit und Sicherheit der Langzeittherapie der Eosinophilen-Ösophagitis mit einer neuen sich im Mund auflösenden Fluticason-Tablette (APT-1011): Ergebnisse einer internationalen randomisierten doppel-blinden Placebo-kontrollierten Phase 2b-Studie. <i>Zeitschrift Für Gastroenterologie</i> , 2020, 58, .	0.2	2
51	Association Between <i>Helicobacter pylori</i> Exposure and Decreased Odds of Eosinophilic Esophagitis—A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2185-2198.e3.	2.4	51
52	Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1477-1488.e10.	2.4	16
53	Conjunctivitis in dupilumab clinical trials. <i>British Journal of Dermatology</i> , 2019, 181, 459-473.	1.4	288
54	Clinical Features at Baseline Cannot Predict Symptom Response to Placebo in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2126-2128.e1.	2.4	6

#	ARTICLE	IF	CITATIONS
55	Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis. <i>Gut</i> , 2019, 68, 2152-2160.	6.1	42
56	One-Hour Esophageal String Test: A Nonendoscopic Minimally Invasive Test That Accurately Detects Disease Activity in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 1614-1625.	0.2	57
57	Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1501-1509.	2.1	22
58	Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 666-673.e8.	2.4	51
59	Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration. <i>Gastroenterology</i> , 2019, 156, 838-842.	0.6	25
60	RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2019, 156, 592-603.e10.	0.6	182
61	Contributions From Gastroenterology: Acid Peptic Disorders, Barrett's Esophagus and Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2018, 154, 1209-1214.	0.6	0
62	Impact on Health-Related Quality of Life in Adults with Eosinophilic Gastritis and Gastroenteritis: A Qualitative Assessment. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1148-1157.	1.1	19
63	Assessing Adherence and Barriers to Long-Term Elimination Diet Therapy in Adults with Eosinophilic Esophagitis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1756-1762.	1.1	70
64	Editorial: long-term effectiveness of elimination diet therapy for eosinophilic oesophagitis is the glass half full or half empty?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 135-136.	1.9	0
65	New Developments in the Diagnosis, Therapy, and Monitoring of Eosinophilic Esophagitis. <i>Current Treatment Options in Gastroenterology</i> , 2018, 16, 15-26.	0.3	9
66	Eosinophilic Esophagitis Reference Score Accurately Identifies Disease Activity and Treatment Effects in Children. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1056-1063.	2.4	86
67	Prospective assessment of disease-specific quality of life in adults with eosinophilic esophagitis. <i>Ecological Management and Restoration</i> , 2018, 31, .	0.2	34
68	Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 477-488.	3.7	135
69	Comparison of endoscopy and radiographic imaging for detection of esophageal inflammation and remodeling in adults with eosinophilic esophagitis. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 962-968.	0.5	20
70	Future Directions in Eosinophilic Esophagitis. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2018, 28, 111-122.	0.6	7
71	Epidemiology and Natural History of Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2018, 154, 319-332.e3.	0.6	472
72	Authors' response. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 747-748.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Oral delivery of fluticasone powder improves esophageal eosinophilic inflammation and symptoms in adults with eosinophilic esophagitis. <i>Ecological Management and Restoration</i> , 2018, 31, .	0.2	11
74	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. <i>Gastroenterology</i> , 2018, 155, 1022-1033.e10.	0.6	712
75	Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 130-138.e1.	1.5	45
76	Biological therapies for eosinophilic gastrointestinal diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 24-31.e2.	1.5	37
77	How to Approach a Patient With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2018, 155, 601-606.	0.6	19
78	Summary of the updated international consensus diagnostic criteria for eosinophilic esophagitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 281-284.	0.5	68
79	Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1714-1729.e3.	2.4	33
80	Endoscopic diagnosis and treatment of disorders of upper esophageal sphincter function. <i>Techniques in Gastrointestinal Endoscopy</i> , 2018, 20, 139-145.	0.3	1
81	Sa1151 - Baseline Characteristics and Correlation Between Dysphagia and Disease Activity in Patients with Eosinophilic Esophagitis in a Randomized, Placebo-Controlled, Phase 2 Dupilumab Trial. <i>Gastroenterology</i> , 2018, 154, S-259.	0.6	6
82	Medical Nutrition Therapy for Patients With Advanced Systemic Sclerosis (MNT PASS): A Pilot Intervention Study. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 41, 678-684.	1.3	26
83	Functional Lumen Imaging Probe for the Management of Esophageal Disorders: Expert Review From the Clinical Practice Updates Committee of the AGA Institute. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 325-334.	2.4	177
84	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1314-1315.	2.4	0
85	A Randomized, Double-Blind, Placebo-Controlled Trial of a Fluticasone Propionate Orally Disintegrating Tablet in Adult and Adolescent Patients with Eosinophilic Esophagitis: A Phase 1/2A Safety and Tolerability Study. <i>Gastroenterology</i> , 2017, 152, S195.	0.6	11
86	Clarifying misunderstandings and misinterpretations about proton pump inhibitor-responsive oesophageal eosinophilia. <i>Gut</i> , 2017, 66, 1173-1174.	6.1	3
87	White Paper AGA: Drug Development for Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1173-1183.	2.4	37
88	Application of the Functional Lumen Imaging Probe to Esophageal Disorders. <i>Current Treatment Options in Gastroenterology</i> , 2017, 15, 10-25.	0.3	16
89	Editorial: oesophageal dilation in eosinophilic oesophagitis“can and should, but when and how?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 556-557.	1.9	1
90	Clinical Features at Baseline are Not Clearly Associated with Symptomatic Placebo Response in Adolescents and Adults with Eosinophilic Esophagitis During a Placebo Run-in Period of a Double-Blind, Randomized, Controlled Trial of Budesonide Oral Suspension. <i>Gastroenterology</i> , 2017, 152, S854.	0.6	3

#	ARTICLE	IF	CITATIONS
91	American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection. <i>Gastroenterology</i> , 2017, 152, 271-275.	0.6	178
92	Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2017, 152, 776-786.e5.	0.6	166
93	How I Approach the Management of Eosinophilic Esophagitis in Adults. <i>American Journal of Gastroenterology</i> , 2017, 112, 197-199.	0.2	5
94	Improvement in Esophageal Distensibility in Response to Medical and Diet Therapy in Eosinophilic Esophagitis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e119.	1.3	74
95	Creating a multi-center rare disease consortium – the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). <i>Translational Science of Rare Diseases</i> , 2017, 2, 141-155.	1.6	30
96	An Overview of Dietary Therapies for the Treatment of Eosinophilic Esophagitis. <i>Gastroenterology and Hepatology</i> , 2017, 13, 381-383.	0.2	0
97	Advances in the endoscopic evaluation of eosinophilic esophagitis. <i>Current Opinion in Gastroenterology</i> , 2016, 32, 325-331.	1.0	6
98	Evaluation of esophageal distensibility in eosinophilic esophagitis: an update and comparison of functional lumen imaging probe analytic methods. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1844-1853.	1.6	52
99	Narrow-caliber esophagus of eosinophilic esophagitis: difficult to define, resistant to remedy. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 1149-1150.	0.5	7
100	2015 David Y. Graham Lecture: The First Two Decades Of Eosinophilic Esophagitis – From Acid Reflux To Food Allergy. <i>American Journal of Gastroenterology</i> , 2016, 111, 770-776.	0.2	13
101	Diagnosis and Treatment of Eosinophilic Esophagitis in Adults. <i>American Journal of Medicine</i> , 2016, 129, 924-934.	0.6	25
102	Substantial Variability in Biopsy Practice Patterns Among Gastroenterologists for Suspected Eosinophilic Gastrointestinal Disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1842-1844.	2.4	19
103	Evaluation of Esophageal Motility Utilizing the Functional Lumen Imaging Probe. <i>American Journal of Gastroenterology</i> , 2016, 111, 1726-1735.	0.2	181
104	Severity of endoscopically identified esophageal rings correlates with reduced esophageal distensibility in eosinophilic esophagitis. <i>Endoscopy</i> , 2016, 48, 794-801.	1.0	68
105	Proton pump inhibitor-responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 631-633.	1.5	53
106	953 Safety and Efficacy of Oral Budesonide Suspension for Maintenance Therapy in Eosinophilic Esophagitis: Results From a Prospective Open-Label Study of Adolescents and Adults. <i>Gastroenterology</i> , 2016, 150, S188.	0.6	10
107	Editorial: Reflux While Running: Something to Belch About. <i>American Journal of Gastroenterology</i> , 2016, 111, 947-948.	0.2	1
108	Prospective assessment of the diagnostic utility of esophageal brushings in adults with eosinophilic esophagitis. <i>Ecological Management and Restoration</i> , 2016, 29, 48-53.	0.2	15

#	ARTICLE	IF	CITATIONS
109	Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2016, 150, 581-590.e4.	0.6	251
110	Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. <i>Gut</i> , 2016, 65, 524-531.	6.1	279
111	Should wheat, barley, rye, and/or gluten be avoided in a 6-food elimination diet?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1011-1014.	1.5	34
112	Editorial: expanding a narrow perspective on narrow calibre oesophagus in eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 147-148.	1.9	1
113	Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. <i>Arthritis Research and Therapy</i> , 2015, 17, 194.	1.6	48
114	Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1000-1010.	1.9	76
115	Esophageal Microbiome in Eosinophilic Esophagitis. <i>PLoS ONE</i> , 2015, 10, e0128346.	1.1	134
116	Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 379-386.	8.2	55
117	Eosinophilic esophagitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 699.	1.0	0
118	Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 500-507.	1.5	253
119	How Do Gastroenterologists Assess Overall Activity of Eosinophilic Esophagitis in Adult Patients?. <i>American Journal of Gastroenterology</i> , 2015, 110, 402-414.	0.2	44
120	813 Oral Budesonide Suspension Significantly Improves Dysphagia and Esophageal Eosinophilia: Results From a Multicenter Randomized Double-Blind Placebo-Controlled Trial in Adolescents and Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2015, 148, S-157.	0.6	7
121	Esophagogastric junction distensibility measurements during Heller myotomy and POEM for achalasia predict postoperative symptomatic outcomes. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 522-528.	1.3	137
122	Therapeutic strategies in eosinophilic esophagitis: Induction, maintenance and refractory disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 829-839.	1.0	19
123	American Gastroenterological Association Institute Guideline on the Management of Acute Diverticulitis. <i>Gastroenterology</i> , 2015, 149, 1944-1949.	0.6	249
124	Oral Fluticasone Powder Improves Histopathology in Adults With Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2015, 110, S724-S725.	0.2	2
125	Role of Advanced Diagnostics for Eosinophilic Esophagitis. <i>Digestive Diseases</i> , 2014, 32, 78-83.	0.8	17
126	Development and Validation of a Symptom-Based Activity Index for Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2014, 147, 1255-1266.e21.	0.6	221

#	ARTICLE	IF	CITATIONS
127	Eosinophilic Esophagitisâ€”Emerging Epidemic or Misdiagnosed Malady?. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 597-598.	2.4	6
128	Eosinophilic Esophagitis. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 329-344.	1.0	11
129	Clinical Implications and Pathogenesis of Esophageal Remodeling in Eosinophilic Esophagitis. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 297-316.	1.0	103
130	T-Helper 2 Cytokines, Transforming Growth Factor Î²1, and Eosinophil Products Induce Fibrogenesis and Alter Muscle Motility in Patients With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2014, 146, 1266-1277.e9.	0.6	114
131	Endoscopic assessment of eosinophilic esophagitis. <i>Techniques in Gastrointestinal Endoscopy</i> , 2014, 16, 20-25.	0.3	6
132	Eosinophilic Esophagitis. <i>Gastroenterology Clinics of North America</i> , 2014, 43, xv-xvi.	1.0	0
133	Su1862 Systematic, Endoscopic Assessment Demonstrates Increased Fibrostenotic and Decreased Inflammatory Esophageal Features in Adults Compared With Children With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2013, 144, S-494.	0.6	2
134	Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. <i>Gut</i> , 2013, 62, 489-495.	6.1	671
135	Esophageal Distensibility as a Measure of Disease Severity in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1101-1107.e1.	2.4	248
136	ACG Clinical Guideline: Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE). <i>American Journal of Gastroenterology</i> , 2013, 108, 679-692.	0.2	983
137	Diet therapy for eosinophilic esophagitis. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 407-415.	1.0	12
138	Functional luminal imaging probe topography: an improved method for characterizing esophageal distensibility in eosinophilic esophagitis. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 97-107.	1.4	77
139	Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 634-642.	1.9	120
140	Emerging drugs for eosinophilic esophagitis. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 353-364.	1.0	10
141	Editorial: Should Patients With Suspected Eosinophilic Esophagitis Undergo a Therapeutic Trial of Proton Pump Inhibition?. <i>American Journal of Gastroenterology</i> , 2013, 108, 373-375.	0.2	28
142	Eosinophilic esophagitis: are we just scratching the surface?. <i>Gastroenterology and Hepatology</i> , 2013, 9, 611-2.	0.2	1
143	Eosinophilic gastrointestinal diseasesâ€”clinically diverse and histopathologically confounding. <i>Seminars in Immunopathology</i> , 2012, 34, 715-731.	2.8	23
144	Therapeutic End Points in Eosinophilic Esophagitis: Is Elimination of Esophageal Eosinophils Enough?. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 750-752.	2.4	48

#	ARTICLE	IF	CITATIONS
145	Working with the US Food and Drug Administration: Progress and timelines in understanding and treating patients with eosinophilic esophagitis. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 617-619.	1.5	46
146	Su1135 Validity, Usability, and Acceptability of the Eosinophilic Esophagitis Quality of Life Scale for Adults (EoE-QOL-A). <i>Gastroenterology</i> , 2012, 142, S-434.	0.6	5
147	Elimination Diet Effectively Treats Eosinophilic Esophagitis in Adults; Food Reintroduction Identifies Causative Factors. <i>Gastroenterology</i> , 2012, 142, 1451-1459.e1.	0.6	572
148	Pediatric and adult eosinophilic esophagitis: similarities and differences. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 477-490.	2.7	212
149	Temporal trends in the relative prevalence of dysphagia etiologies from 1999-2009. <i>World Journal of Gastroenterology</i> , 2012, 18, 4335.	1.4	94
150	Eosinophilic Esophagitis: Treatment Approach in Adults. , 2012, , 395-408.		0
151	A 78-Year-Old Man With Difficulty Swallowing. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 470-474.	2.4	8
152	Eosinophilic Esophagitis and Gastroesophageal Reflux Disease: There and Back Again. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 99-101.	2.4	29
153	Mechanical Properties of the Esophagus in Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2011, 140, 82-90.	0.6	314
154	Expression of mast cell-associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1307-1308.e3.	1.5	74
155	Eosinophilic esophagitis: Updated consensus recommendations for children and adults. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 3-20.e6.	1.5	1,839
156	Long Term Maintenance Therapy With Dietary Restriction in Adults With Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2011, 140, S-180-S-181.	0.6	16
157	Qualitative Assessment of Patient-reported Outcomes in Adults With Eosinophilic Esophagitis. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 769-774.	1.1	65
158	Manometric features of eosinophilic esophagitis in esophageal pressure topography. <i>Neurogastroenterology and Motility</i> , 2011, 23, 208-e111.	1.6	125
159	The adult eosinophilic oesophagitis quality of life questionnaire: a new measure of health-related quality of life. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 790-798.	1.9	104
160	Dilation in eosinophilic esophagitis: to do or not to do?. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 713-714.	0.5	38
161	Esophagogastric junction distensibility assessed with an endoscopic functional luminal imaging probe (EndoFLIP). <i>Gastrointestinal Endoscopy</i> , 2010, 72, 272-278.	0.5	211
162	Esophageal Dilation in Eosinophilic Esophagitis: Effectiveness, Safety, and Impact on the Underlying Inflammation. <i>American Journal of Gastroenterology</i> , 2010, 105, 1062-1070.	0.2	277

#	ARTICLE	IF	CITATIONS
163	Advances in diagnostic testing for gastroesophageal reflux disease. World Journal of Gastroenterology, 2010, 16, 3750.	1.4	17
164	Histopathologic Variability in Children With Eosinophilic Esophagitis. American Journal of Gastroenterology, 2009, 104, 716-721.	0.2	148
165	Eosinophilic esophagitis: Pathophysiology and optimal management. Current Gastroenterology Reports, 2009, 11, 175-181.	1.1	16
166	Histopathologic Variability in Children With Eosinophilic Esophagitis. American Journal of Gastroenterology, 2009, 104, 716-721.	0.2	31
167	Acid Reflux Detection and Symptom-Reflux Association Using 4-Day Wireless pH Recording Combining 48-Hour Periods Off and On PPI Therapy. American Journal of Gastroenterology, 2008, 103, 1631-1637.	0.2	32
168	ACG Practice Guidelines: Esophageal Reflux Testing. American Journal of Gastroenterology, 2007, 102, 668-685.	0.2	323
169	New Technologies for the Evaluation of Esophageal Motility Disorders: Impedance, High-resolution Manometry, and Intraluminal Ultrasound. Gastroenterology Clinics of North America, 2007, 36, 531-551.	1.0	11
170	Treatment of eosinophilic esophagitis: Drugs, diet, or dilation?. Current Gastroenterology Reports, 2007, 9, 181-188.	1.1	15
171	The evolving role of the wireless pH capsule in evaluation of patients with GERD. Current GERD Reports, 2007, 1, 151-156.	0.1	0
172	Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointestinal Endoscopy, 2006, 64, 313-319.	0.5	438
173	Review article: modern technology in the diagnosis of gastro-oesophageal reflux disease - Bilitec, intraluminal impedance and Bravo capsule pH monitoring. Alimentary Pharmacology and Therapeutics, 2006, 23, 12-24.	1.9	35
174	Ambulatory pH Monitoring: New Advances and Indications. Gastroenterology and Hepatology, 2006, 2, 835-842.	0.2	4
175	Effectiveness of esophageal dilation for symptomatic cricopharyngeal bar. Gastrointestinal Endoscopy, 2005, 61, 148-152.	0.5	68
176	Four-Day Bravo pH Capsule Monitoring With and Without Proton Pump Inhibitor Therapy. Clinical Gastroenterology and Hepatology, 2005, 3, 1083-1088.	2.4	84
177	Esophagogastric Junction Morphology Predicts Susceptibility to Exercise-Induced Reflux. American Journal of Gastroenterology, 2004, 99, 1430-1436.	0.2	82
178	EUS and histopathologic correlates in eosinophilic esophagitis. Gastrointestinal Endoscopy, 2001, 54, 373-377.	0.5	97
179	Chronic Intestinal Pseudo-Obstruction. Digestive Diseases, 2000, 18, 83-92.	0.8	28
180	Deaths after living related liver transplantation. Liver Transplantation, 2000, 6, 250-250.	1.3	18

#	ARTICLE	IF	CITATIONS
181	Pathophysiology of achalasia. Current Gastroenterology Reports, 1999, 1, 198-202.	1.1	42
182	The Enteric Nervous System. New England Journal of Medicine, 1996, 334, 1106-1115.	13.9	708
183	Esophagus: anatomy and developmental and structural anomalies. , 0, , 717-739.		0
184	Esophagus: Anatomy and Developmental and Structural Anomalies. , 0, , 152-159.		1
185	Motility Disorders of the Esophagus. , 0, , 160-177.		0